Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE:LLY) and Roche Holding AG's (OTC:RHHBY) failed to improve symptoms of Alzheimer's disease (AD) in a Phase 2/3 study led by Washington University School of Medicine reported last year.
- Now, the study researchers say they have evidence that Roche's gantenerumab could help a subset of patients.
- In trial participants with dominantly inherited Alzheimer's disease (DIAD), which causes early onset of memory loss and other symptoms, Roche's drug lowered biomarkers and neurodegeneration, Washington University said in a study published in Nature Medicine.
- The study did not show evidence of a cognitive benefit to people with DIAD.
- Washington University has now launched an extension of the study, which will allow patients on Roche's drug to continue taking it and to have their symptoms monitored over time.
- Patients in the original trial were randomized to receive either Lilly's solanezumab, Roche's drug, or a placebo and then tracked for up to seven years.
- The 52 patients who took gantenerumab showed a reduction of amyloid plaques in the brain and lower amounts of another protein, tau, the researchers reported.
- Even after disappointing top-line findings of the Phase 2/3 study of solanezumab and gantenerumab, Roche still did not want to give up on its anti-amyloid antibody.
- But Lilly scrapped its plans to pursue a submission for solanezumab in people with dominantly inherited Alzheimer's disease.
- Price Action: LLY shares closed at $222.67, and RHHBF closed at $389.8 on Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!